133 related articles for article (PubMed ID: 23188123)
1. Pharmacokinetics of treprostinil diolamine in subjects with end-stage renal disease on or off dialysis.
Jenkins A; Wang-Smith L; Marbury T; Laliberte K
J Cardiovasc Pharmacol; 2013 Apr; 61(4):272-6. PubMed ID: 23188123
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers.
Jones A; Wang-Smith L; Pham T; Laliberte K
J Cardiovasc Pharmacol; 2014 Mar; 63(3):227-32. PubMed ID: 24603117
[TBL] [Abstract][Full Text] [Related]
3. The effect of different meal compositions on the oral bioavailability of treprostinil diolamine in healthy volunteers.
Lim A; Wang-Smith L; Kates J; Laurent A; Kumar P; Laliberte K
J Clin Pharm Ther; 2013 Dec; 38(6):450-5. PubMed ID: 23927483
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension.
White RJ; Torres F; Allen R; Jerjes C; Pulido T; Yehle D; Howell M; Laliberte K; Marier JF; Tapson VF
J Cardiovasc Pharmacol; 2013 Jun; 61(6):474-81. PubMed ID: 23328389
[TBL] [Abstract][Full Text] [Related]
5. An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment.
Peterson L; Marbury T; Marier J; Laliberte K
J Clin Pharm Ther; 2013 Dec; 38(6):518-23. PubMed ID: 24033615
[TBL] [Abstract][Full Text] [Related]
6. Lack of a pharmacokinetic interaction between treprostinil diolamine and sildenafil in healthy adult volunteers.
Gotzkowsky SK; Kumar P; Mottola D; Laliberte K
J Cardiovasc Pharmacol; 2013 May; 61(5):444-51. PubMed ID: 23429588
[TBL] [Abstract][Full Text] [Related]
7. Open label study of escalating doses of oral treprostinil diethanolamine in patients with systemic sclerosis and digital ischemia: pharmacokinetics and correlation with digital perfusion.
Shah AA; Schiopu E; Hummers LK; Wade M; Phillips K; Anderson C; Wise R; Boin F; Seibold JR; Wigley F; Rollins KD
Arthritis Res Ther; 2013 Apr; 15(2):R54. PubMed ID: 23597147
[TBL] [Abstract][Full Text] [Related]
8. A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration.
Kumar P; Thudium E; Laliberte K; Zaccardelli D; Nelsen A
Clin Pharmacokinet; 2016 Dec; 55(12):1495-1505. PubMed ID: 27286723
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
10. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion.
Wade M; Baker FJ; Roscigno R; DellaMaestra W; Hunt TL; Lai AA
J Clin Pharmacol; 2004 Jan; 44(1):83-8. PubMed ID: 14681345
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.
Wade M; Baker FJ; Roscigno R; DellaMaestra W; Arneson CP; Hunt TL; Lai AA
J Clin Pharmacol; 2004 May; 44(5):503-9. PubMed ID: 15102871
[TBL] [Abstract][Full Text] [Related]
12. Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience.
Coons JC; Miller T
Ther Adv Respir Dis; 2018; 12():1753466618766490. PubMed ID: 29609511
[TBL] [Abstract][Full Text] [Related]
13. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
LeVarge BL; Channick RN
Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
[TBL] [Abstract][Full Text] [Related]
14. Treprostinil for the treatment of pulmonary arterial hypertension.
Torres F; Rubin LJ
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
[TBL] [Abstract][Full Text] [Related]
15. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers.
Gotzkowsky SK; Dingemanse J; Lai A; Mottola D; Laliberte K
J Clin Pharmacol; 2010 Jul; 50(7):829-34. PubMed ID: 20133511
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
[TBL] [Abstract][Full Text] [Related]
17. Midodrine treatment in a patient with treprostinil-induced hypotension receiving hemodialysis.
Drambarean B; Bielnicka P; Alobaidi A
Am J Health Syst Pharm; 2019 Jan; 76(1):13-16. PubMed ID: 31381098
[TBL] [Abstract][Full Text] [Related]
18. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion.
McSwain CS; Benza R; Shapiro S; Hill N; Schilz R; Elliott CG; Zwicke DL; Oudiz RJ; Staszewski JP; Arneson CP; Wade M; Zaccardelli D; McLaughlin V
J Clin Pharmacol; 2008 Jan; 48(1):19-25. PubMed ID: 18094217
[TBL] [Abstract][Full Text] [Related]
19. Oral treprostinil for the treatment of pulmonary arterial hypertension.
de Lartigue J
Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
